Schedule 13D ownership disclosure

BridgeBio Oncology Therapeutics Inc

Common Stock · CUSIP: 107924102

Event date: 2025-08-11

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Helix Holdings II LLCReported CIK 0001869101

    Shares: 4,528,186.00 · Class: 5.7%

  • Cormorant Global Healthcare Master Fund, LPReported CIK 0001618442

    Shares: 5,952,356.00 · Class: 7.5%

  • Cormorant Global Healthcare GP, LLCReported CIK 0001618451

    Shares: 5,952,356.00 · Class: 7.5%

  • Bihua ChenReported CIK 0001599214

    Shares: 17,878,594.00 · Class: 22.6%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001213900-25-075307
Form type
SCHEDULE 13D/A
Filer
BridgeBio Oncology Therapeutics, Inc.
CIK
CIK 1869105
Filed
Aug 13, 2025
Reporting period
Aug 11, 2025
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub